Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Sep;25(3):326-330.
doi: 10.3350/cmh.2018.0063. Epub 2018 Dec 4.

Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: A case report

Rahul Kumar  1 , John Chen Hsiang  1 , Jessica Tan  1 , Prem Harichander Thurairajah  1
Affiliations
Case Reports

Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: A case report

Rahul Kumar et al. Clin Mol Hepatol. 2019 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors have no conflicts to disclose.

Figures

Figure 1.
Figure 1.
Changes in serum sodium and creatinine levels before, during and after treatment with Viekira Pak (VP)+ribavirin. The sodium levels dropped to 99 mmol/L in at week 9 after initiation of VP+ribavirin from pre-treatment level of 140 mmol/L. Serum creatinine levels were within the normal range before, during and at presentation in emergency department at week 9 of treatment.
Figure 2.
Figure 2.
Changes in serum levels of components of liver function tests before, during and after treatment with Viekira Pak (VP)+ribavirin combination. There was more than 10 fold rise in alanine transaminases and aspartate transaminases levels at week 9, compared to week 4 on treatment. Serum total bilirubin levels also rose to more than 10 fold from pre-treatment levels.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–965. - PubMed
    1. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–1603. - PubMed
    1. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-460/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–1982. - PubMed
    1. American Associations for the Study of Liver Diseases (AASLD) HCV guidance: recommendations for testing, managing, and treating hepatitis C. AASLD web site, < https://www.hcvguidelines.org/treatment-naive/gt1>. Accessed 15 Jun 2018. - PubMed
    1. European Association for the Study of the Liver (EASL) EASL recommendations on treatment of hepatitis C 2016 Summary. EASL web site, < http://www.easl.eu/medias/cpg/HCV2016/Summary.pdf>. Accessed 15 Jun 2018. - PubMed

MeSH terms